Dr. Zhongwei Sun (Ph.D.) is Principle Research Scientist and Supervisor of Medical Research in Cellular Biomedicine Group (CBMG, NASDAQ listed), Shanghai, China. He worked on manipulation of neurogenesis in adult mice' brain by genetically controlling Proliferation and Differentiation of Neural Stem Cells in Center for Regenerative Therapies of Dresden, and Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, and obtained his Ph.D. degree of Stem Cell biology from Technique University of Dresden, Germany. He is experienced in R&D of new drugs for neurodegenerative disease, such as Alzheimer's disease, and Psychological disease, for example Anxiety. For the recent two years, he is fascinated working on R&D of Cell Therapy for both degenerative disease and cancer. He has successfully done investigation of efficacy of human adipose derived Mesenchymal Stem cells (clinical grade) on degenerative disease, Chronic Obstructive Pulmonary Disease (COPD), and Knee Osteoarthritis (KOA), with both small and big animal models. And contributed to the application of IND (Investigational New Drug) to both cFDA and FDA.
T cell immuno-therapeutic methods for liquid and solid tumors; CAR-T (Chimeric Antigen Receptor Therapy);TCR-T (T cell receptor Therapy); TIL (Tumor infiltrating lymphocyte); Stem cell therapeutic methods for CNS disease.